Laila is specialised in Intellectual Property law, with a particular interest in pharmaceutical patents cases. Laila has worked on litigation for major pharmaceutical companies in the UK, as well as co-ordinating global patent enforcement strategies for major pharmaceutical companies, working with global clients and local law firms situated throughout the world.
She has advised on a number of significant patent disputes in the pharmaceutical sector, relating to medicinal products (varying from small molecules drugs to monoclonal antibody therapies to baby formula) and medical devices. She worked extensively with medical experts and seen a number of cases through UK court proceedings. She is also experienced in the drafting of pan-European patent settlement/licensing agreements, including an understanding of relevant competition law issues.
Laila has excellent relationships with IP counsel in numerous firms across Europe, and advises clients on their pan-European (and global) patent enforcement strategy, including preliminary injunction applications and main action proceedings.
She was also involved in a Bahamian copyright appeal which was successful at the Privy Council.
Laila's experience includes advising:
- Biogen, Roche and Genentech in a Patents Court action relating to MabThera®, an antibody that binds to CD20 for the treatment for rheumatoid arthritis, follicular lymphoma and chronic lymphocytic leukaemia
- two major listed pharmaceutical companies in relation to the co-ordination of their pan-European/global patent enforcement strategies in the face of generic threats to a number of their key drugs
- AbbVie in a UK Court action concerning AbbVie's blockbuster anti-TNFα antibody Humira®
Laila has a Biochemistry degree (1st), University of Bristol; PhD in Molecular Biology and Biochemistry, Manchester University; Diploma in IP Law, Oxford University; is a solicitor advocate. She was a Postdoctoral Researcher, DNAelectronics, undertaking proof of concept research with a diagnostic device.